Prosecution Insights
Last updated: November 04, 2026
Application No. 18/690,788

ANTI-ROR1 ANTIBODIES AND USES THEREOF

Non-Final OA §112
Filed
Mar 11, 2024
Priority
Sep 12, 2021 — provisional 63/243,150 +1 more
Examiner
PRIEST, JESSICA MARIE
Art Unit
1642
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Immunorizon Ltd.
OA Round
1 (Non-Final)
Grant Probability
Favorable
1-2
OA Rounds

Examiner Intelligence

Grants only 0% of cases
0%
Career Allowance Rate
0 granted / 0 resolved
-60.0% vs TC avg
Minimal +0% lift
Without
With
+0.0%
Interview Lift
resolved cases with interview
Typical timeline
Avg Prosecution
26 currently pending
Career history
33
Total Applications
across all art units
This examiner has no resolved cases yet (career too new); statute-level performance unavailable. The Grant Probability card shows Tech Center averages instead.

Office Action

§112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claim Status Claims 1-12 are pending and currently under consideration for patentability under 37 CFR 1.104. Priority This application is a 371 of PCT/IL2022/050983 (filed on 09/11/2022) which claims benefit of Provisional U.S. Application No. 63/243,150 (filed on 09/12/2021). Applicant’s claim for the benefit of a prior-filed application under 35 U.S.C. 119(e) or under 35 U.S.C. 120, 121, 365(c), or 386(c) is acknowledged. Claims 1-12 have an effective filing date of 09/12/2021 corresponding to Provisional U.S. Application No. 63/243,150. Information Disclosure Statement The information disclosure statement(s) filed on 05/29/2024 and 05/13/2025 has/have been considered. Signed copies are enclosed. Specification Applicant is reminded of the proper language and format for an abstract of the disclosure. The abstract should be in narrative form and generally limited to a single paragraph on a separate sheet within the range of 50 to 150 words in length. The abstract should describe the disclosure sufficiently to assist readers in deciding whether there is a need for consulting the full patent text for details. The language should be clear and concise and should not repeat information given in the title. It should avoid using phrases which can be implied, such as, “The disclosure concerns,” “The disclosure defined by this invention,” “The disclosure describes,” etc. In addition, the form and legal phraseology often used in patent claims, such as “means” and “said,” should be avoided. Claim Objections Claims 1-3 and 12 are objected to because of the following informalities: Claim 1: all instances of “the amino acid sequences of one” should be replaced with “the amino acid sequence of one”. Claim 1: all instances of “the LCDR3” should be replaced with “and the LCDR3”. Claim 2: “respectively” should be added to the end of the claim. Claim 3: “a Fv, a scFv” should be replaced with “an Fv, an scFv”. Claim 12: “a metastasis of a cancer” should be replaced with “a metastatic cancer”. Appropriate correction is required. Claim Rejections - 35 USC § 112(a) The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claims 1 and 3-12 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, because the specification, while being enabling for anti-ROR1 antibodies as recited in Tables 1A/1B or claim 2 and a method of ameliorating ROR1-expressing cancers comprising administering to a subject said antibodies, does not reasonably provide enablement for anti-ROR1 antibodies comprising mutated and truncated CDRs as recited in claim 1 and a method of treating and preventing all diseases. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to use the invention commensurate in scope with these claims. As a general rule, enablement must be commensurate with the scope of claim language. MPEP 2164.08 states, “The Federal Circuit has repeatedly held that “the specification must teach those skilled in the art how to make and use the full scope of the claimed invention without undue experimentation’.” In re Wright, 999 F.2d 1557, 1561, 27 USPQ2d 1510, 1513 (Fed. Cir. 1993)” (emphasis added). The “make and use the full scope of the invention without undue experimentation” language was repeated in 2005 in Warner-Lambert Co. v. Teva Pharmaceuticals USA Inc., 75 USPQ2d 1865, and Scripps Research Institute v. Nemerson, 78 USPQ2d 1019 asserts: “A lack of enablement for the full scope of a claim, however, is a legitimate rejection.” The principle was explicitly affirmed most recently in Auto. Tech. Int’l, Inc. v. BMW of N. Am., Inc., 501 F.3d 1274, 84 USPQ2d 1108 (Fed. Cir. 2007), Monsanto Co. v. Syngenta Seeds, Inc., 503 F.3d 1352, 84 U.S.P.Q.2d 1705 (Fed. Cir. 2007), and Sitrick v. Dreamworks, LLC, 516 F.3d 993, 85 USPQ2d 1826 (Fed. Cir. 2008). See also In re Cortright, 49 USPQ2d 1464, 1466 and Bristol-Myers Squibb Co. v. Rhone-Poulenc Rorer Inc., 49 USPQ2d 1370. The factors to be considered in determining whether a disclosure meets the enablement requirement of 35 U.S.C. 112, first paragraph, have been described in In re Wands, 8 USPQ2d 1400 (Fed. Cir. 1988). Among these factors are: (1) the nature or the invention; (2) the state of the prior art; (3) the relative skill of those in the art; (4) the predictability or unpredictability of the art; (5) the breadth of the claims; (6) the amount of direction or guidance presented; (7) the presence or absence of working examples; and (8) the quantity of experimentation necessary. When the above factors are weighed, it is the examiner’s position that one skilled in the art could not practice the invention without undue experimentation. Some experimentation is not fatal; the issue is whether the amount of experimentation is “undue”; see In re Vaeck, 20 USPQ2d 1438, 1444. (1) The nature of the invention The invention is drawn to anti-ROR1 antibodies comprising numerous CDR combinations with mutations and truncations and a method of treating all diseases comprising administering to a subject said antibodies, subject matter that is highly complex and unpredictable. The invention involves complex and unpredictable technology. Sevy and Meiler (Antibodies: computer-aided prediction of structure and design of function, Microbiol Spectrum, 2014) state “antibodies pose formidable challenges for protein structure prediction and design due to their large size and highly flexible loops in the complementarity-determining regions” (Pg. 1, Abstract, lines 6-9). Consequently, the relationship between an antibody’s structure and function is unpredictable. Furthermore, US20200299381A1 (published 2020-09-24, hereinafter referred to as US ‘381; IDS filed on 05/29/2024, Cite No. 1) teaches anti-ROR1 antibodies are useful in the treatment of cancer (¶ 0003) but does not mention other diseases such as autoimmune diseases, GvHD, viral infections, or bacterial infections. Therefore, the relationship between anti-ROR1 antibodies and the treatment of a variety of diseases is not readily established. Thus, the invention is directed towards unpredictable and complex subject matter wherein practicing the claimed invention requires the anti-ROR1 antibody sequence and the specific disease treated. (2) The state of the prior art and (5) the breadth of the claims Claim 1 is drawn to an anti-ROR1 antibody comprising 6 CDRs from groups (i)-(vii). Each group permits 2-3 alternative amino acid sequences for each CDR of varying lengths and sequence identity. Therefore, as instantly claimed, the CDRs can be heavily mutated and/or truncated. Claims 3-4 specify the antibody format. Claim 5 teach a composition of the antibody. Claims 6-8 teach an encoding nucleic acid for said antibody (claim 6) in a vector (claim 7) and a host cell comprising said vector (claim 8). Chiu et al. (Antibody Structure and Function: The Basis for Engineering Therapeutics. Antibodies (Basel). 2019 Dec 3;8(4):55) teach CDRs as defined by Kabat, Chothia, and IMGT encompass different numbers of amino acid residues (Pg. 12, Table 1) that are important for antibody conformation and antigen binding (Pg. 12, entire ¶ 2). Even minor changes in the amino acid sequences of the heavy and light variable regions, particularly in the CDRs, may dramatically affect antigen-binding function as evidenced by Rudikoff et al. (Proc. Natl. Acad. Sci. USA, 79(6):1979-1983, March 1982). Rudikoff et al. teach that the alteration of a single amino acid in the CDR of a phosphocholine-binding myeloma protein resulted in the loss of antigen-binding function. These teachings indicate amino acid mutations within CDRs can completely change the antigen recognition of the antibody i.e. result in nonfunctional anti-ROR1 antibodies. Johnson and Wu (Methods in Molecular Biology, Antibody Engineering: Methods and Protocols, Vol. 248, Pg. 11-25, 2004) teach that complete Kabat CDRs of antibodies CDRH1-3 and CDRL1-3 are at least 5, 16, 8, 11, 7, and 9 amino acid residues in length respectively (Pg. 12, entire ¶ 2). For example. HCDR2 of group (ii) can have 14 or 17 amino acid residues (see SEQ ID NOs: 30-31). The HCDR2 containing 14 amino acid resides is smaller than the HCDR2 length of as defined by Kabat and would not be expected to confer antigen binding to an antibody framework (i.e. the CDR having a truncation), barring evidence to the contrary. It amounts to no more than a mutated Kabat CDR. These teachings indicate it is not readily established that truncations within CDRs do not affect the antigen recognition of the antibody i.e. result in nonfunctional anti-ROR1 antibodies. Although the alternative CDR sequences as recited in claim 1 may correspond to recognized CDR definitions (e.g. Kabat, Chothia, IGMT, etc.), Applicant does not provide evidence that every claimed CDR combination when incorporated into an antibody framework would maintain its ability to bind its antigen, ROR1. Claim 1 recites a wider range of embodiments that goes beyond the support from the instant specification. The instant specification teaches the VH and VL for the 7 distinct anti-ROR1 antibodies in Tables 1A and 1B respectively, wherein the VH and VL combinations are identical to those recited in claim 2. While the CDRs as recited in claim 1 are encompassed by the VH and VL sequences of Tables 1A and 1B, the additional context of the framework regions allows a person having ordinary skill in the art to predictably make anti-ROR1 antibodies that retain their function of ROR1-binding. Therefore, only the anti-ROR1 antibodies as recited in Tables 1A/1B or claim 2 are enabled. Claim 9 is drawn to a method of treating a disease comprising administering to a subject a composition comprising the anti-ROR1 antibody. Since the disease is not specified, claim 9 reads on the treatment of all diseases, an incredibly broad claim encompassing numerous diseases with widely different treatment plans. Claim 10 specifies the disease is a cancer, autoimmune disease, GvHD, viral infection, or bacterial infection. Claims 11-12 specifies a solid or non-solid cancer (claim 11) and a metastasis of the cancer (claim 12). Even for a given disease type, such as cancer, the recitation is still broad. For example, “many agents, including radiation, chemicals, and viruses” can induce cancer formation i.e. cancer does not have one cause and it is not a single disease (Cooper, The Development and Causes of Cancer, The Cell: A Molecular Approach, 2000, Pg. 4, first ¶). Kayal (Cancer Therapy: A Brief Outline, Annals of the National Academy of Medical Sciences, 2019) teaches surgery or radiotherapy can be used to target solid tumors but are not effective for hematological malignancies; hematopoietic stem cell transplant can treat hematological malignancies (Pg. 139, Fig. 1, shows different treatments for different cancers). As a consequence to the vast number of different cancers, not all treatments plans are effective across the board. The instant specification states the term “treating” refers “to therapeutic treatment, including prophylactic or preventative measures, wherein the object is to prevent or slow down (lessen) an undesired physiological change associated with a disease or condition” (¶ 0102, emphasis added). Treatment as defined by the instant specification therefore reads on ameliorating and preventing the disease. While anti-ROR1 antibodies are well-known in the prior art, it is not readily established which antibodies are relevant for the treatment and prevention of diseases including cancers, autoimmune diseases, GvHD, viral infections, or bacterial infections. For example, as mentioned above, US ‘381 indicates anti-ROR1 antibodies can be used in ameliorating a variety of ROR1-expressing cancer like blood malignancies, melanoma, neuroblastoma, and lung cancer (¶ 0003). This teaching does not indicate anti-ROR1 antibodies are broad anti-cancer reagents and thus limit their therapeutic potential to ROR1-expressing cancer. In addition, US ‘381 does not specifically mention autoimmune diseases, GvHD, viral infections, or bacterial infections. A person having ordinary skill in the art would need to know which anti-ROR1 antibodies are effective in the treatment and prevention of the recited diseases (e.g. specific cancers, autoimmune diseases, GvHD, viral infections, and bacterial infections that can be treated and/or prevented) vs. which simply bind ROR1 but have no therapeutic utility. According to Potter (The failure of cancer chemoprevention, Carcinogenesis, 2014), cancer can be random in nature, making it incredibly difficult to prevent the formation of cancer in its entirety (Pg. 974, column 1, entire Introduction). Consequently, “we have a multiplicity of theories of carcinogenesis that do not provide clear understanding of what is causal and, thus, an incomplete understanding of the role these agents might play in cancer. As a result, cancer chemoprevention is an almost universal failure” (Potter, Pg. 974, column 1, Introduction, ¶ 2-3). These teachings demonstrate the unpredictable nature of cancer and the difficulty in preventing it. It is not readily established that the anti-ROR1 antibodies could prevent cancer. Claim 9-12 recites a wider range of embodiments that goes beyond the support from the instant specification. The instant application is silent on use of the instantly claimed anti-ROR1 antibodies in treatment of disease, instead relying on the prior art. The prior art indicates anti-ROR1 antibodies are useful in ameliorating but not preventing ROR1-expressing cancer. In addition, the prior art does not provide evidence to the Examiner’s knowledge regarding the treatment and prevention of autoimmune diseases, GvHD, bacterial infections, and viral infections prior to the effective filing date of the instant application. Therefore, while ameliorating ROR1-expressing cancer is enabled, treatment and prevention of all diseases are not enabled as instantly claimed. Therefore, it is concluded that the instant specification provides support for anti-ROR1 antibodies as recited in Tables 1A/1B or claim 2. The prior art gives support for a method of ameliorating ROR1-expressing cancers comprising administering to a subject said antibodies. Accordingly, claims 1 and 3-12 are incredibly broad and drawn to (i) anti-ROR1 antibodies comprising mutated and truncated CDRs and (ii) treating and preventing all diseases comprising administering to a subject said antibodies, the full scope of which is not enabled by instant specification as currently claimed. (3) The relative skill of those in the art, (4) the predictability or unpredictability of the art This invention is in a class of invention which the CAFC has characterized as "the unpredictable arts such as chemistry and biology". Mycogen Plant Sci., Inc. v. Monsanto Co., 243 F.3d 1316, 1330 (Fed. Cir. 2001). For a person having ordinary skill in the art, i.e. someone with a PhD and/or MD (the relative skill of those in the art), the predictability of applying anti-ROR1 antibodies comprising mutated and truncated CDRs to treat or prevent all diseases would be low (the predictability or unpredictability of the art) given that: It is not predictable how CDR mutations and truncations as recited in claim 1 would affect its binding affinity (see Rudikoff) i.e. ability to bind ROR1. Furthermore, the structure of an antibody cannot be reliably predicted from function alone (see Sevy and Meiler). There is a lack of enablement as Applicant failed to disclose if all CDR combinations result in functional antibodies (i.e. they retain their ROR1-binding) and how to predictably use such molecules in treating and preventing all diseases. It is not readily established that anti-ROR1 antibodies are relevant for the treatment and prevention of all diseases (see US ‘381 and Potter). A person having ordinary skill in the art would need to determine which antibodies are effective for the treatment and prevention of an undisclosed disease, an unpredictable endeavor. Consequently, claims 1 and 3-12 are directed to complex and unpredictable fields, where the successful treatment and prevention of all diseases comprising administrating to the subject anti-ROR1 antibodies comprising mutated and truncated CDRs cannot be readily extrapolated from the limited number of disclosed examples in the instant application and prior art. The instant specification provides support for anti-ROR1 antibodies as recited in Tables 1A/1B or claim 2. The prior art gives support for a method of ameliorating ROR1-expressing cancers comprising administering to a subject said antibodies. Therefore, anti-ROR1 antibodies as recited in Tables 1A/1B or claim 2 and a method of ameliorating ROR1-expressing cancers comprising administering to a subject said antibodies is supported by the specification. However, anti-ROR1 antibodies comprising mutated and truncated CDRs as recited in claim 1 and a method of treating and preventing all diseases comprising administering to a subject said antibodies is not supported. (6) The amount of direction or guidance presented, (7) the presence or absence of working examples, and (8) the quantity of the experimentation The instant specification provides support for anti-ROR1 antibodies as recited in Tables 1A/1B or claim 2. The prior art gives support for a method of ameliorating ROR1-expressing cancers comprising administering to a subject said antibodies. The specification does not provide any additional examples or guidance on how anti-ROR1 antibodies comprising mutated and truncated CDRs can be used to treat and prevent the variety of diseases claimed (the amount of direction or guidance presented and the presence or absence of working examples). The specification of the instant application does not provide support for the entire scope of the claims. It is not readily established which anti-ROR1 antibodies comprising CDR mutations and truncations as recited in claim 1 would affect its binding affinity (see Rudikoff) i.e. ability to bind ROR1 and thus their efficacies in the treatment and prevention of diseases. Consequently, it would require extensive screening and testing to determine which antibodies not only bind ROR1 but have therapeutic benefits; this is not routine and would therefore require undue experimentation (the quantity of the experimentation, see MPEP 2164.06). Claims 1 and 3-12 are not enabled because a person having ordinary skill in the art as of the effective filing date of the application would not be able to make functional anti-ROR1 antibodies comprising mutated and truncated CDRs as recited in claim 1 and use said antibodies in a method of treating and preventing all diseases with a predictability of success for the reasons outlined above. Claim 2 delineates the full VH and VL sequences for the anti-ROR1 antibodies (in agreement with Tables 1A and 1B of the instant specification) and is therefore not included in this rejection. Claim Rejections - 35 USC § 112(b) The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claim 11 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Regarding claim 11, the phrase “non-solid (diffuse) cancer” renders the claim indefinite because it is unclear whether the limitation in the parentheses of the phrase are part of the claimed invention. See MPEP § 2173.05(d). For the purposes of claim interpretation, the phrase “non-solid (diffuse) cancer” will be treated as “non-solid cancer” to indicate the contents of the parentheses merely states a non-limiting example. Art-Free Subject Matter It is noted that instant SEQ ID NOs for the VH and VL of claim 2 were thoroughly searched corresponding to the limitations of the claim and are free of prior art. While the CDRs of claim 1 are encompassed by the SEQ ID NOs of claim 2, it is impossible for the examiner to search all CDR combinations as instantly claimed. There are hundreds of possible CDR combinations. Therefore, it cannot be said definitively that all CDR combinations of claim 1 are free of the prior art. Allowable Subject Matter Claim 2 is objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. Conclusion Claims 1-12 are pending. Claims 1-3 and 12 are objected to. Claims 1 and 3-12 are rejected. No claims are allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jessica M Priest whose telephone number is (571)272-8469. The examiner can normally be reached Mon-Fri 8am-5pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Samira Jean-Louis can be reached at (571) 270-3503. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /J.M.P./Examiner, Art Unit 1642 /SAMIRA J JEAN-LOUIS/Supervisory Patent Examiner, Art Unit 1642
Read full office action

Prosecution Timeline

Mar 11, 2024
Application Filed
Oct 23, 2026
Non-Final Rejection mailed — §112 (current)

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
Grant Probability
Low
PTA Risk
Based on 0 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month